<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The treatment of advanced non-clear cell renal carcinoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The treatment of advanced non-clear cell renal carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The treatment of advanced non-clear cell renal carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Toni K Choueiri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sumanta K Pal, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H7944250"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although many advances have been made in the treatment of metastatic non-clear cell renal cell carcinoma (RCC), there are limited high-quality data to help inform management due to the infrequency of these tumors. </p><p>Non-clear cell RCCs (or RCCs of variant histology) are characterized by morphology, growth pattern, cell of origin, and where they are known, the histochemical and biologic bases that underlie the different types of tumors.</p><p>The most common subtypes of non-clear cell RCC include the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Papillary</p><p class="bulletIndent1"><span class="glyph">●</span>Chromophobe</p><p class="bulletIndent1"><span class="glyph">●</span>Collecting duct (including medullary carcinoma)</p><p class="bulletIndent1"><span class="glyph">●</span>Translocation carcinomas</p><p class="bulletIndent1"><span class="glyph">●</span>Unclassified RCC</p><p></p><p>Sarcomatoid RCC is not considered a distinct subtype because sarcomatoid features can be seen in any histologic subtype of RCC.</p><p>The kidney can also give rise to other types of malignancies, including non-Hodgkin lymphoma, soft tissue sarcomas (eg, leiomyosarcoma, liposarcoma), and carcinoid tumors; their treatment is based on the tumor type rather than their origination from the kidney. The diagnosis and treatment of these cancers are discussed separately. (See  <a class="medical medical_review" href="/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a> and  <a class="medical medical_review" href="/d/html/7736.html" rel="external">"Clinical presentation and diagnosis of retroperitoneal soft tissue sarcoma"</a> and  <a class="medical medical_review" href="/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts"</a>.)</p><p>This topic will discuss the management of non-clear cell RCC. The epidemiology, pathology, and pathogenesis of these tumors are discussed separately, as is the treatment of clear cell and sarcomatoid RCC. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128561.html" rel="external">"Renal cell carcinoma with sarcomatoid features"</a> and  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128561.html" rel="external">"Renal cell carcinoma with sarcomatoid features"</a> and  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a>.)</p><p></p><p class="headingAnchor" id="H1093823989"><span class="h1">GOALS OF THERAPY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized disease </strong>– The general approach to treatment of localized (stage I to III  (<a class="graphic graphic_table graphicRef110735" href="/d/graphic/110735.html" rel="external">table 1</a>)) non-clear cell renal cell carcinoma (RCC) is similar to that of clear cell RCC. Surgical resection offers the best chance of cure, although some small renal masses can be observed or ablated. More extensive discussions on the treatment of localized RCC are covered separately. (See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Localized renal cell carcinoma'</a> and  <a class="medical medical_review" href="/d/html/2985.html" rel="external">"Definitive surgical management of renal cell carcinoma"</a> and  <a class="medical medical_review" href="/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced or metastatic disease </strong>– Historically, treatment of patients with advanced, unresectable, or metastatic non-clear cell RCC has been palliative; however, prognosis and treatment of these patients are evolving in the era of checkpoint inhibitor immunotherapy, and some of these patients may have durable responses. As an example, for patients with certain histologic subtypes (ie, sarcomatoid features), immunotherapy significantly improves survival and complete response rates, suggesting the potential for cure. (See <a class="local">'Non-clear cell RCC with sarcomatoid features'</a> below.)</p><p></p><p class="headingAnchor" id="H485744238"><span class="h1">AVAILABLE AGENTS</span><span class="headingEndMark"> — </span>Systemic therapy is usually given either as monotherapy or as combinations of agents from the following classes:</p><p class="bulletIndent1"><span class="glyph">●</span>Programmed cell death protein 1 (PD-1) checkpoint inhibitors (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Programmed cell death ligand 1 (PD-L1) checkpoint inhibitors (<a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Anticytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibodies (<a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Inhibitors of the vascular endothelial growth factor (VEGF) pathway, or antiangiogenic therapy (<a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Mammalian target of rapamycin (mTOR) inhibitors (<a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> and <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapy (platinum-based regimens)</p><p></p><p>Interleukin-2 (IL-2) does not have an established treatment role in those with non-clear cell renal cell carcinoma (RCC) due to limited efficacy [<a href="#rid2">2-5</a>]. </p><p>The specific treatment approach for patients with non-clear cell RCC is based on histologic subtype and is discussed in further detail below:</p><p class="bulletIndent1"><span class="glyph">●</span>Papillary RCC (see <a class="local">'Papillary renal cell carcinoma'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Chromophobe RCC (see <a class="local">'Chromophobe renal cell carcinoma'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Collecting duct and renal medullary carcinoma (see <a class="local">'Collecting duct and renal medullary carcinoma'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Translocation RCC (see <a class="local">'Translocation renal cell carcinoma'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Unclassified RCC (see <a class="local">'Unclassified renal cell carcinoma'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>RCC (clear cell and non-clear cell) with sarcomatoid features (see  <a class="medical medical_review" href="/d/html/128561.html" rel="external">"Renal cell carcinoma with sarcomatoid features"</a>)</p><p></p><p class="headingAnchor" id="H1675780631"><span class="h1">PAPILLARY RENAL CELL CARCINOMA</span><span class="headingEndMark"> — </span>Tumors with papillary renal cell carcinoma (RCC) have unique histopathology, molecular alterations, and clinical presentation. These characteristics may influence treatment response to particular systemic agents, such as immunotherapy or other targeted therapies. Historically, patients with papillary RCC have been classified as type I or type II mostly based on cytopathologic findings [<a href="#rid6">6-11</a>]. We also classify papillary RCCs as MET-driven versus independent, based on molecular alterations in the MET gene and inclusion criteria from clinical trials [<a href="#rid12">12,13</a>].</p><p>Further details on the pathology of papillary renal cell tumors are discussed separately. (See  <a class="medical medical_review" href="/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Papillary carcinomas'</a> and  <a class="medical medical_review" href="/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes"</a>.)</p><p class="headingAnchor" id="H1843198442"><span class="h2">Approach to therapy</span><span class="headingEndMark"> — </span>Our approach to treatment is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with treatment-naïve advanced or metastatic papillary RCC, we suggest either checkpoint inhibitor immunotherapy-based regimens or a vascular endothelial growth factor receptor (VEGFR) inhibitor as initial therapy. Both agents are reasonable options as these approaches have not been directly compared in a clinical trial in this population. A choice is based on patient comorbidities, disease risk stratification, and patient preferences. While many patients will be treated with immunotherapy, it is generally not used in patients with a poor performance status, poorly controlled autoimmune disease, or those who prefer oral therapies; such patients may be candidates for a VEGFR inhibitor. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those who choose immunotherapy, we suggest <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> rather than other immunotherapy-based regimens. extrapolating from the approach used for those with clear cell RCC. Other options include <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> plus nivolumab, and single-agent pembrolizumab  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>). (See <a class="local">'Preferred immunotherapy regimens'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those who choose targeted antiangiogenic therapy with VEGFR inhibitors or are ineligible for immunotherapy, we suggest <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> rather than other VEGFR inhibitors. <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">Sunitinib</a> is a reasonable alternative for those who decline cabozantinib, as no overall survival benefit has been demonstrated for cabozantinib over sunitinib. For those with International Metastatic RCC Database Consortium (IMDC) poor-risk disease  (<a class="graphic graphic_table graphicRef116130" href="/d/graphic/116130.html" rel="external">table 3</a>), alternative, but less preferred, agents include <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> or <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>  (<a class="graphic graphic_table graphicRef68554" href="/d/graphic/68554.html" rel="external">table 4</a>). (See <a class="local">'Targeted agents'</a> below and  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Risk stratification'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">Bevacizumab</a> plus <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> is preferred therapy for patients with papillary RCC due to hereditary leiomyomatosis eligible for antiangiogenic therapy. (See  <a class="medical medical_review" href="/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes", section on 'Hereditary leiomyomatosis and renal cell cancer syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A MET-inhibitor based approach to MET-driven papillary tumors is evolving. (See <a class="local">'Experimental agents (MET inhibitors)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our approach to subsequent therapy depends on initial treatment:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have progressed on initial immunotherapy-based regimens, we offer targeted antiangiogenic therapy not previously received. (See <a class="local">'Targeted agents'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those who have progressed on targeted antiangiogenic therapy without prior exposure to immunotherapy, we offer an immunotherapy-based regimen. The approach is similar to those who receive immunotherapy as initial treatment. (See <a class="local">'Nivolumab plus ipilimumab'</a> below.)</p><p></p><p class="headingAnchor" id="H1822152250"><span class="h2">Preferred immunotherapy regimens</span></p><p class="headingAnchor" id="H3206654626"><span class="h3">Nivolumab plus ipilimumab</span><span class="headingEndMark"> — </span>For those with papillary renal carcinoma who choose immunotherapy as initial treatment, we offer the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>. This approach is extrapolated from a phase III trial (CheckMate 214) in those with clear cell RCC, where this combination conferred an overall survival benefit, high rates of complete response, and prolonged treatment-free survival [<a href="#rid14">14,15</a>]. Further randomized studies are needed to compare immunotherapy with VEGFR inhibitors in those with non-clear cell RCC to establish the optimal initial treatment approach, and patients should be encouraged to enroll in clinical trials whenever possible. Further details on the use of nivolumab plus ipilimumab in those with clear cell carcinoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab plus ipilimumab'</a>.)</p><p>Data for <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in those with papillary RCC are limited to observational studies conducted in heterogeneous populations of non-clear cell RCC [<a href="#rid16">16-18</a>]. In a phase IIIb/IV prospective study (CheckMate 920), 52 patients with non-clear cell RCC were treated with nivolumab plus ipilimumab. Among the 18 patients with papillary histology, objective responses were seen in five patients (28 percent) [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H68858810"><span class="h3">Lenvatinib plus pembrolizumab</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is effective initial therapy in patients with advanced papillary RCC. In a single-arm, international phase II trial (KEYNOTE-B61), 158 patients with systemic therapy-naïve advanced non-clear cell RCC of varying histologies were treated with lenvatinib plus pembrolizumab [<a href="#rid20">20</a>]. At median follow-up of 15 months, among the subgroup of 93 patients with papillary histology, objective responses were seen in 50 patients (54 percent), including eight complete responses (9 percent), and one-year PFS was 67 percent. </p><p class="headingAnchor" id="H3571974084"><span class="h3">Cabozantinib plus nivolumab</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> is clinically effective in patients with papillary RCC. As an example, a single-arm phase II trial evaluated nivolumab plus cabozantinib in 47 patients with non-clear cell RCC of varying histologies [<a href="#rid21">21</a>]. At median follow-up of 13 months, among the subgroup of 32 patients with papillary RCC, objective responses were observed in 15 patients (47 percent). Additionally, objective responses were seen in all five patients with fumarate hydratase (<em>FH)</em>-deficient RCC. </p><p class="headingAnchor" id="H220877597"><span class="h3">Pembrolizumab</span><span class="headingEndMark"> — </span>Single-agent <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>) is active in papillary RCC, as survival and response rates are higher than those previously reported with antiangiogenic agents or chemotherapy [<a href="#rid22">22-24</a>].</p><p>The efficacy of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>) in papillary RCC was demonstrated in an open-label, nonrandomized phase II trial (KEYNOTE-427, Cohort B) [<a href="#rid24">24</a>]. In this study of 165 patients with non-clear cell histologies, of which 118 tumors (72 percent) were papillary subtype, pembrolizumab was administered at 200 mg intravenous (IV) every three weeks for up to two years, or until disease progression or toxicity. At median follow-up of approximately 11 months, objective response rates were 29 percent for those with papillary RCC, 24 percent for those with intermediate/poor-risk disease of any subtype, and 35 percent for those with a positive combined positive score (CPS) of any subtype. Among responders, the median duration of response was 29 months, and a majority (57 percent) had durable responses at 18-month follow-up. In the entire study population, estimated two-year overall survival and progression-free survival (PFS) rates were 58 and 19 percent, respectively. Grade ≥3 toxicity occurred in 17 percent of patients.</p><p class="headingAnchor" id="H1858380384"><span class="h2">Less preferred immunotherapy regimens</span></p><p class="headingAnchor" id="H3660863325"><span class="h3">Nivolumab</span><span class="headingEndMark"> — </span>We do not offer single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> for the treatment of papillary RCC due to limited efficacy with this agent and better activity noted with other immunotherapy-based regimens. Data from observational studies [<a href="#rid17">17,22,25</a>] initially suggested response rates between 14 and 30 percent. However, in a phase II clinical trial (HCRN GU16-260, Cohort B), among the subgroup of 19 patients with papillary RCC, objective responses were only seen in one patient (5 percent) [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H115958726"><span class="h2">Targeted agents</span><span class="headingEndMark"> — </span>Targeted therapies, such as antiangiogenic agents (VEGFR inhibitors) and mammalian target of rapamycin (mTOR) inhibitors have also demonstrated efficacy in papillary RCC. The choice of regimen depends on disease context, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients who choose VEGFR inhibitors or who are ineligible for immunotherapy, we suggest <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> rather than other VEGFR inhibitors, as this approach improved PFS compared with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> in a randomized trial (PAPMET). For those who decline cabozantinib, sunitinib is a reasonable alternative, as an overall survival benefit was not demonstrated for cabozantinib over sunitinib in PAPMET. In addition, the efficacy of sunitinib over the mTOR inhibitor <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> has been established in randomized clinical trials. (See <a class="local">'Sunitinib'</a> below and <a class="local">'Cabozantinib'</a> below.)</p><p></p><p class="bulletIndent1">Alternative, but less preferred, agents for those with poor-risk disease  (<a class="graphic graphic_table graphicRef116130" href="/d/graphic/116130.html" rel="external">table 3</a>) include mTOR inhibitors such as <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> or <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>  (<a class="graphic graphic_table graphicRef68554" href="/d/graphic/68554.html" rel="external">table 4</a>). (See <a class="local">'Mammalian target of rapamycin inhibitors (everolimus and temsirolimus)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with papillary RCC due to hereditary leiomyomatosis eligible for antiangiogenic therapy, we offer <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> plus <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>. This preference is based on the results of a nonrandomized trial that demonstrated high response rates in this population. There are limited data regarding other inhibitors of the VEGF pathway in this rare subgroup. (See <a class="local">'Bevacizumab with or without erlotinib'</a> below.)</p><p></p><p class="headingAnchor" id="H541783442"><span class="h3">Vascular endothelial growth factor inhibitors</span></p><p class="headingAnchor" id="H2797485147"><span class="h4">Cabozantinib</span><span class="headingEndMark"> — </span>In patients with treatment-naïve advanced papillary RCC, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> improved PFS and objective response rates compared with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> in a randomized trial. </p><p>Based on initial observational data that suggested clinical efficacy with <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> [<a href="#rid27">27-29</a>], a randomized, open-label phase II trial (SWOG 1500; PAPMET) was conducted in 152 patients with papillary RCC [<a href="#rid30">30</a>]. A majority of patients had treatment-naïve disease (93 percent), IMDC intermediate- or poor-risk disease  (<a class="graphic graphic_table graphicRef116130" href="/d/graphic/116130.html" rel="external">table 3</a>) (75 percent), and either type I and type II histology (approximately 18 and 54 percent, respectively). Patients were randomly assigned to receive either cabozantinib, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a>, or savolitinib.</p><p>Compared with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> improved PFS (median nine versus six months, HR 0.60, 95% CI 0.37-0.97) and objective response rates (23 versus 4 percent), which included two complete responses (5 percent). Cabozantinib also demonstrated a nonstatistically significant trend towards higher overall survival compared with sunitinib, which would be clinically meaningful if true (median 20 versus 16 months, HR 0.84, 95% CI 0.47-1.51). Clinical PFS benefit for cabozantinib was seen for patients with both type I and type II histologies, regardless of classification based on local or central pathologic assessment. Grade ≥3 treatment-related toxicities were similar between cabozantinib and sunitinib (74 versus 69 percent), and no new toxicity signals were identified. </p><p>Of note, neither of the MET inhibitors, <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a> or savolitinib, improved PFS compared with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, and the treatment arms for these agents were closed to accrual after a prespecified futility analysis. </p><p>The use of <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> in clear cell histologies is discussed separately. (See  <a class="medical medical_review" href="/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Cabozantinib'</a>.)</p><p class="headingAnchor" id="H2446418232"><span class="h4">Sunitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">Sunitinib</a> is an effective initial therapy that improves survival and response rates in patients with papillary renal cell carcinoma, based on several phase II randomized trials directly comparing this agent with the mTOR inhibitor <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid31">31-35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a phase II trial (ASPEN), 108 previously untreated patients were randomly assigned to either <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid32">32</a>]. Two-thirds of the study population had papillary carcinoma; other patients had chromophobe, translocation, unclassified, and clear cell RCC with sarcomatoid histologies. At a median follow-up of 13 months, relative to everolimus, sunitinib improved PFS in the total study population (median PFS 8.3 versus 5.6 months, two-year PFS 23 versus 9 percent, hazard ratio [HR] 1.41, 80% CI 1.03-1.92) and had higher objective response rates (18 versus 9 percent). While the difference in overall survival was not statistically significant, it would be clinically meaningful if true (median overall survival 32 versus 13 months, HR 1.12, 95% CI 0.7-2.1).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate phase II trial (ESPN), 73 patients with metastatic non-clear cell RCC were randomly assigned to <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, with crossover to the alternate agent at disease progression [<a href="#rid33">33</a>]. At a median follow-up of approximately two years, overall survival was similar between the two treatment arms (median overall survival 16.2 versus 14.9 months). Objective responses were seen in 9 percent (3 of 33 patients) initially treated with sunitinib and in 3 percent (1 of 35 patients) initially treated with everolimus. Following crossover, four additional partial responses were observed for each agent.</p><p></p><p class="headingAnchor" id="H1614024055"><span class="h4">Bevacizumab with or without erlotinib</span><span class="headingEndMark"> — </span>There are limited data for the efficacy of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> alone or in combination with <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> in those with sporadic papillary RCC. One study attempted to evaluate bevacizumab in a phase II trial of patients with metastatic papillary RCC, but it was closed due to poor patient accrual [<a href="#rid36">36</a>].</p><p>However, the combination of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> plus <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> has substantial efficacy and is the preferred initial systemic therapy in those with papillary RCC due to hereditary leiomyomatosis. These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes", section on 'Hereditary leiomyomatosis and renal cell cancer syndrome'</a>.)</p><p class="headingAnchor" id="H2437627142"><span class="h4">Less preferred antiangiogenic agents</span><span class="headingEndMark"> — </span>Observational studies and early phase II trials have suggested modest efficacy for the VEGFR inhibitors <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> and <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a> [<a href="#rid37">37-40</a>]. While some experts may reasonably offer these agents, we do not prefer pazopanib or axitinib as initial therapy in those with papillary RCC, given the stronger evidence for other antiangiogenic agents. (See <a class="local">'Targeted agents'</a> above.)</p><p class="headingAnchor" id="H630295080"><span class="h3">Mammalian target of rapamycin inhibitors (everolimus and temsirolimus)</span><span class="headingEndMark"> — </span>Data suggest that mTOR inhibitors, such as <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> and <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>, may be effective in patients with poor-risk non-clear cell RCC. However, these agents are becoming less preferred given the demonstrated efficacy of immunotherapy in patients with intermediate- and poor-risk disease. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Intermediate- and poor-risk disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-arm open-label phase II trial (RAPTOR) of 88 patients with treatment-naïve papillary RCC treated with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, the stable disease rate was 65 percent; median PFS and overall survival were approximately 4 and 21 months, respectively [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a phase III trial (ARCC) of 626 patients with advanced RCC randomly assigned to <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a> or interferon alfa, temsirolimus improved overall survival (median overall survival 12 versus 4 months) among the subset of 124 patients (20 percent) with predominantly papillary histology [<a href="#rid42">42,43</a>].</p><p></p><p class="headingAnchor" id="H20988735"><span class="h2">Experimental agents (MET inhibitors)</span><span class="headingEndMark"> — </span>Although agents that inhibit the c-MET pathway have activity against papillary RCC, data are limited, and this approach remains experimental.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crizotinib</strong> – <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">Crizotinib</a> was evaluated in 23 patients with type I papillary RCC in a phase II study (CREATE) [<a href="#rid44">44</a>]. In the four patients with a MET alteration, two achieved a partial response, with durations of approximately two and three years, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Foretinib</strong> – In a phase II trial of the investigational MET inhibitor foretinib that included 74 patients with papillary RCC, the objective response rate was 13.5 percent, and the median PFS was nine months [<a href="#rid45">45</a>]. The overall survival rate was 70 percent at one year.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Savolitinib</strong> – In a randomized phase III trial (SAVOIR) of 60 patients with MET-driven papillary RCC, compared with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, the selective MET inhibitor savolitinib improved overall response rates (27 versus 7 percent) and had a better toxicity profile [<a href="#rid12">12</a>]. However, the study, which was prematurely terminated, did not detect a statistical difference in progression-free or overall survival between the two treatment arms. </p><p></p><p class="bulletIndent1">In a single-arm phase II trial (CALYPSO) of 41 patients with advanced papillary RCC, the combination of savolitinib with the PD-L1 inhibitor <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> demonstrated a confirmed response rate of 29 percent, which failed to meet the primary endpoint (confirmed response rate of 50 percent or greater) [<a href="#rid46">46</a>]. However, in the subgroup with MET-driven papillary RCC, the confirmed response rate for the combination was 53 percent.</p><p></p><p class="headingAnchor" id="H205374322"><span class="h1">LESS COMMON SUBTYPES</span></p><p class="headingAnchor" id="H10685658"><span class="h2">Chromophobe renal cell carcinoma</span><span class="headingEndMark"> — </span>For those with chromophobe tumors, we offer initial treatment with targeted agents such as mammalian target of rapamycin (mTOR) inhibitors (eg, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>) or vascular endothelial growth factor receptor (VEGFR) inhibitors (eg, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>). Limited data also show some efficacy for <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> plus <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> in these tumors [<a href="#rid47">47</a>]. Alternative options include combination therapy such as <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or lenvatinib and everolimus. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Everolimus</strong> – Some patients with chromophobe tumors have genetic alterations that lead to upregulation of the mTOR pathway, such as mutations on chromosome 17 leading to loss of the folliculin gene (ie, Birt-Hogg-Dubé syndrome). (See  <a class="medical medical_review" href="/d/html/100661.html" rel="external">"Birt-Hogg-Dubé syndrome", section on 'Kidney tumors'</a>.)</p><p></p><p class="bulletIndent1">Inhibition of this pathway with agents such as <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> represents a logical therapeutic approach in these tumors [<a href="#rid48">48</a>]. Further details on molecular alterations found in chromophobe tumors are discussed separately. (See  <a class="medical medical_review" href="/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Chromophobe carcinomas'</a>.)</p><p></p><p class="bulletIndent1">The randomized phase II trial (ASPEN) comparing <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> in 108 patients with non-clear cell renal cell carcinoma (RCC) included a subset of 16 patients (15 percent) with chromophobe histology [<a href="#rid32">32</a>]. In this subset, everolimus improved overall response rates relative to sunitinib (33 versus 10 percent). Median progression-free survival (PFS) for everolimus was longer relative to sunitinib (12 versus 6 months); this result was not statistically significant, likely due to the small number of patients, but it would be clinically meaningful if true.</p><p></p><p class="bulletIndent1">The use of <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> in other RCC subtypes is discussed separately. (See  <a class="medical medical_review" href="/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Everolimus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular endothelial growth factor inhibitors</strong> – Limited data suggest that VEGFR inhibitors have activity in patients with chromophobe RCC [<a href="#rid32">32,33,49,50</a>]. A single-arm, open-label, phase II trial evaluated <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> in 57 patients with non-clear clear cell histologies [<a href="#rid49">49</a>]. In this subset of five patients (9 percent) with chromophobe histologies, there were two partial responses (40 percent), and the median PFS was approximately 13 months. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenvatinib</strong><strong> plus </strong><strong>pembrolizumab</strong> – The combination of <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is effective initial therapy in patients with advanced chromophobe RCC. This combination was evaluated in a single-arm phase II trial (KEYNOTE-B61) of 158 patients with systemic-therapy naïve advanced non-clear cell RCC of varying histology. At median follow-up of 15 months, among the subgroup of 29 patients with chromophobe histology, objective responses were seen in eight patients (28 percent), and one-year PFS was 53 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenvatinib</strong><strong> plus </strong><strong>everolimus</strong> – <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">Lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> is an option in patients with chromophobe RCC either as initial therapy or subsequent therapy after progression on a VEGFR inhibitor, as this combination inhibits both the VEGF and mTOR pathway [<a href="#rid51">51</a>]. In a single-arm phase II trial of 31 patients with treatment-naïve non-clear cell RCC treated with lenvatinib plus everolimus, objective responses were seen in four out of nine patients with chromophobe RCC (44 percent) [<a href="#rid52">52</a>]. </p><p></p><p class="bulletIndent1">We also offer this approach extrapolating from randomized trials conducted in those with clear cell histologies, which conferred a PFS benefit compared with either <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> alone. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Lenvatinib plus everolimus'</a> and  <a class="medical medical_review" href="/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Lenvatinib plus everolimus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bevacizumab</strong><strong> plus </strong><strong>everolimus</strong><strong> </strong>– <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">Bevacizumab</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> has also shown efficacy in those with chromophobe tumors. In a phase II trial of 35 patients with non-clear cell carcinoma, five had chromophobe tumors [<a href="#rid47">47</a>]. An objective response rate of 29 percent was seen in the total study population, with responses seen in two of five patients with chromophobe tumors (40 percent). Median PFS and overall survival were 11 and 19 months for the total study population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other regimens</strong> – Other regimens have demonstrated limited efficacy in chromophobe RCC. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nivolumab</strong><strong> plus </strong><strong>cabozantinib</strong> – In one phase II trial of 47 patients with advanced non-clear cell RCC treated with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, no objective responses were noted among the subset of seven patients with chromophobe RCC [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bevacizumab</strong><strong> plus </strong><strong>atezolizumab</strong> – In another phase II trial of 60 patients with metastatic RCC with variant histology and/or sarcomatoid features treated with <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> plus <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a>, objective responses were seen in one of ten patients (10 percent) with chromophobe RCC [<a href="#rid53">53</a>]. </p><p></p><p class="headingAnchor" id="H1721858677"><span class="h2">Collecting duct and renal medullary carcinoma</span><span class="headingEndMark"> — </span>For those with collecting duct RCC or renal medullary carcinoma, we suggest cytotoxic chemotherapy as initial therapy rather than VEGFR inhibitors. Options for combinations of platinum-based chemotherapy include <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>; <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> plus gemcitabine; and carboplatin plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>. There are limited data regarding immunotherapy with checkpoint inhibitors, and these agents remain investigational. The initial treatment approach for these histologies is similar to that of metastatic urothelial carcinoma, which is discussed separately. Patients are encouraged to enroll on clinical trials where available. (See  <a class="medical medical_review" href="/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract", section on 'Initial therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Collecting duct renal cell carcinoma </strong>– Collecting duct RCC is an aggressive tumor that has similar biologic features to urothelial carcinoma. Unlike other types of non-clear cell histologies, collecting duct RCCs respond to cytotoxic chemotherapy using platinum-based chemotherapy [<a href="#rid54">54-59</a>]. There are limited clinical trial data evaluating treatment options in this rare tumor, and further studies are needed. (See  <a class="medical medical_review" href="/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Collecting duct tumors'</a>.)</p><p></p><p class="bulletIndent1">In an open-label phase II trial of 23 patients with collecting duct RCC treated with <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, objective responses were seen in six patients (26 percent), and median overall survival was approximately 11 months [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal medullary carcinoma </strong>– Renal medullary carcinoma is an aggressive variant of collecting duct tumors predominantly found in those with sickle cell trait. (See  <a class="medical medical_review" href="/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'SMARCB1-deficient renal cell carcinoma and renal medullary carcinoma'</a> and  <a class="medical medical_review" href="/d/html/7199.html" rel="external">"Sickle cell disease effects on the kidney", section on 'Renal medullary carcinoma'</a> and  <a class="medical medical_review" href="/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Kidney complications'</a>.)</p><p></p><p class="bulletIndent1">Data for effective treatment options are limited to observational studies. Platinum-based chemotherapy is typically administered as initial therapy in a majority of patients, with a wide range of reported activity [<a href="#rid60">60-64</a>]. As an example, in one case series of 52 patients with renal medullary carcinoma, 85 percent (45 patients) were treated with platinum-based chemotherapy, with response rates of approximately 30 percent [<a href="#rid64">64</a>]. Two-year overall survival for the entire study population was 13 percent.</p><p></p><p class="bulletIndent1">Other chemotherapy agents (eg, anthracyclines), immunomodulatory therapy (eg, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>), and VEGFR inhibitors (eg, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>) all have limited activity in this disease [<a href="#rid63">63,65-67</a>].</p><p></p><p class="headingAnchor" id="H1675780766"><span class="h2">Translocation renal cell carcinoma</span><span class="headingEndMark"> — </span>For those with translocation RCC, we suggest initial therapy with <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> rather than a VEGFR inhibitor, based on high objective response rates with this regimen. For patients who decline or are ineligible for decline immunotherapy, a single-agent VEGFR inhibitor (eg, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>) is a reasonable alternative. Due to the rarity of translocation RCC, clinical trials are encouraged where available.</p><p>Translocation RCCs are a rare variant of non-clear cell carcinomas characterized by <em>TFE3</em> gene fusions, leading to activation of microphthalmia-associated transcription factor (<em>MITF</em>). (See  <a class="medical medical_review" href="/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Translocation renal cell carcinoma (MiT/TFE-related RCC)'</a>.)</p><p>There are limited data on the optimal initial therapy for advanced translocation RCC, due to the rarity of this disease. In a phase II trial, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> demonstrated an objective response rate of 67 percent. However, lenvatinib plus pembrolizumab has not been directly compared with single-agent VEGFR inhibitors in randomized trials with this population. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenvatinib</strong><strong> plus </strong><strong>pembrolizumab</strong> – In a single-arm, international phase II trial (KEYNOTE-B61), 158 patients with systemic therapy-naïve advanced non-clear cell RCC of varying histologies were treated with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> [<a href="#rid20">20</a>]. At median follow-up of 15 months, among the subgroup of six patients with papillary histology, objective responses were seen in four patients (67 percent), all of which were partial responses. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sunitinib</strong> – Observational studies support the initial use of <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> in translocation RCC [<a href="#rid68">68,69</a>]. As an example, in an nonrandomized study of approximately 50 patients less than 45 years old with Xp11.2 translocation carcinomas, partial responses were seen in 3 of 11 patients (27 percent) treated with sunitinib versus one of nine patients (11 percent) treated with cytokine therapy (interferon alfa or interleukin 2) [<a href="#rid69">69</a>]. Additionally, the study demonstrated longer PFS in those treated with sunitinib relative to cytokine therapy (median PFS eight versus two months).</p><p></p><p></p><p class="headingAnchor" id="H2103440026"><span class="h2">Unclassified renal cell carcinoma</span><span class="headingEndMark"> — </span>For patients with unclassified RCC, we suggest initial treatment with immunotherapy-based regimens rather than VEGFR inhibitors due to high objective response rates with this approach. Options include combination therapy (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>; <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>) or single-agent immunotherapy (pembrolizumab  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>) or nivolumab  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 5</a>)). Any of these options are appropriate, as there are limited data directly comparing these regimens. (See <a class="local">'Immunotherapy regimens'</a> below.)</p><p>For patients who are ineligible for or decline immunotherapy, VEGFR inhibitors are a reasonable alternative, either as single-agents (eg, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>) or combination therapy (<a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>). (See <a class="local">'Vascular endothelial growth factor receptor inhibitors'</a> below.)</p><p class="headingAnchor" id="H4144444102"><span class="h3">Immunotherapy regimens</span><span class="headingEndMark"> — </span>In prospective clinical trials of patients with unclassified RCC, objective responses are as high as 52 percent for combination therapy and 30 percent for single-agent immunotherapy. Data are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong><strong> plus </strong><strong>ipilimumab</strong> – Some contributors offer <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in those with treatment-naïve unclassified renal cell carcinomas. Observational data suggest activity of nivolumab either with or without ipilimumab in those with unclassified renal cell carcinoma, with reported objective response rates between 20 and 44 percent [<a href="#rid17">17,19</a>]. </p><p></p><p class="bulletIndent1">Additionally, this approach is extrapolated from a phase III trial (CheckMate 214) in those with advanced or metastatic clear cell RCC, where <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> conferred an overall survival benefit over <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, high rates of complete response, and prolonged treatment-free survival [<a href="#rid14">14,15</a>]. Further details on the activity of nivolumab plus ipilimumab in those with clear cell carcinoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Nivolumab plus ipilimumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenvatinib</strong><strong> plus</strong> <strong>pembrolizumab</strong> – The combination of <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is effective initial therapy in patients with advanced unclassified RCC. In a single-arm, international phase II trial (KEYNOTE-B61), 158 patients with systemic therapy-naïve advanced non-clear cell RCC of varying histologies were treated with pembrolizumab plus lenvatinib [<a href="#rid20">20</a>]. At median follow-up of 15 months, among the subgroup of 21 patients with unclassified RCC, objective responses were seen in 11 patients (52 percent), all of which were partial responses. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pembrolizumab</strong><strong> </strong>– In an open-label phase II trial (KEYNOTE-427, Cohort B), 165 patients with non-clear cell RCC were treated with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> as initial therapy [<a href="#rid24">24</a>]. In the subset of 26 patients with unclassified RCC, objective responses were seen in eight patients (31 percent), and a majority had durable responses. Median PFS and overall survival were 3 and 18 months, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong> – <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> is effective in patients with unclassified RCC. In a phase II trial (HCRN GU16-260, Cohort B), 35 patients with advanced non-clear cell RCC were treated with single-agent nivolumab. Among the subgroup of 10 patients with unclassified RCC, objective responses were seen in three patients (30 percent) [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H3028811184"><span class="h3">Vascular endothelial growth factor receptor inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">Sunitinib</a> and <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> as single agents also have efficacy in patients with treatment-naïve unclassified RCC.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sunitinib</strong><strong> </strong>– In two randomized trials, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> improved PFS approximately twofold relative to <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid32">32,33</a>]. In the ASPEN study, which included 22 patients with unclassified RCC, sunitinib had a median PFS of 12 versus 6 months with everolimus [<a href="#rid32">32</a>]. Similarly, in the ESPN study, which included 10 patients with unclassified RCC, sunitinib had a median PFS of nine versus five months with everolimus [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cabozantinib</strong><strong> </strong>– A retrospective study of <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> in 112 patients with non-clear cell histologies included 15 patients with unclassified RCC [<a href="#rid29">29</a>]. In this subset, objective responses were seen in two patients (13 percent), and 12-month overall survival was 36 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other regimens</strong> – Other combinations containing VEGFR inhibitors and the mTOR inhibitor <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> have also shown activity in unclassified RCC.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lenvatinib</strong><strong> plus </strong><strong>everolimus</strong><strong> </strong>– In a phase II trial of 31 patients with non-clear cell RCC treated with the combination of <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, partial responses were seen in one of two patients with unclassified RCC [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bevacizumab</strong><strong> plus </strong><strong>everolimus</strong><strong> </strong>– The combination of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> is an option for patients who are unable to receive <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus everolimus. This combination was evaluated in a phase II trial that included a subset of 23 patients with unclassified RCC containing papillary features. Among these patients, the objective response rate was 43 percent and median PFS was 14 months [<a href="#rid70">70</a>].</p><p></p><p class="headingAnchor" id="H3871087897"><span class="h1">NON-CLEAR CELL RCC WITH SARCOMATOID FEATURES</span><span class="headingEndMark"> — </span>Renal cell carcinoma (RCC) with sarcomatoid differentiation occurs mainly in clear cell histologies but can also be seen in non-clear cell histologies. Patients with advanced or metastatic sarcomatoid RCC typically demonstrate clinical responses to checkpoint inhibitor immunotherapy-based regimens. Further details on the management of non-clear cell RCC with sarcomatoid features are discussed separately. (See  <a class="medical medical_review" href="/d/html/128561.html" rel="external">"Renal cell carcinoma with sarcomatoid features", section on 'Initial therapy (non-clear cell RCC with sarcomatoid features)'</a>.)</p><p class="headingAnchor" id="H274982341"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119821.html" rel="external">"Society guideline links: Cancer of the kidney and ureters"</a>.)</p><p class="headingAnchor" id="H1675781009"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic subtypes of non-clear cell renal carcinoma </strong>– The main subtypes of non-clear cell renal cell carcinoma (RCC) include papillary, chromophobe, collecting duct, unclassified, and translocation carcinomas. Sarcomatoid RCC is not considered a distinct subtype, primarily because sarcomatoid features can be seen in any histologic subtype of RCC. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach </strong>– The specific treatment approach to patients with advanced-stage non-clear cell RCC is based on histologic subtype. Although many advances have been made in the treatment of non-clear cell RCC, there are limited high-quality data to help inform management due to the infrequency of these tumors. Patients should be enrolled in a clinical trial whenever possible. (See <a class="local">'Available agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Papillary renal cell carcinoma </strong>– For patients with advanced papillary RCC, some contributors offer checkpoint inhibitor immunotherapy-based therapy, while others offer a vascular endothelial growth factor (VEGFR) inhibitor as initial therapy. Recognizing that there are limited data directly comparing these approaches, we feel either option is appropriate. (See <a class="local">'Papillary renal cell carcinoma'</a> above and <a class="local">'Approach to therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those who choose immunotherapy, we suggest <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> rather than other immunotherapy-based regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), extrapolating from the approach used for those with clear cell RCC where this combination conferred an overall survival benefit over <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, high rates of complete response, and prolonged treatment-free survival. Other options include <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> plus nivolumab, or single-agent pembrolizumab  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>). (See <a class="local">'Preferred immunotherapy regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those who choose targeted antiangiogenic therapy or are ineligible for immunotherapy, we suggest initial therapy with <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a> rather than other VEGFR inhibitors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Targeted agents'</a> above and  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Risk stratification'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">Bevacizumab</a> plus <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> is the preferred therapy for patients with papillary RCC due to hereditary leiomyomatosis eligible for antiangiogenic therapy. (See  <a class="medical medical_review" href="/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes", section on 'Hereditary leiomyomatosis and renal cell cancer syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chromophobe renal cell carcinoma </strong>– For patients with advanced or metastatic chromophobe RCC, available evidence is limited due to the rarity of these tumors. We offer initial treatment with targeted therapy such as a mammalian target of rapamycin (mTOR) inhibitor (eg, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>) or a VEGFR inhibitor (eg, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>). Alternative options include combination therapy such as <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or lenvatinib plus everolimus. (See <a class="local">'Chromophobe renal cell carcinoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Collecting duct and renal medullary carcinoma </strong>– For patients with advanced or metastatic collecting duct or renal medullary carcinoma, we suggest cytotoxic chemotherapy as initial therapy rather than VEGFR inhibitors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Options for combinations of platinum-based chemotherapy include <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>; <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> plus gemcitabine; and carboplatin plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>. (See <a class="local">'Collecting duct and renal medullary carcinoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Translocation renal cell carcinoma </strong>– For patients with advanced or metastatic translocation RCC, we suggest <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> rather than a single-agent VEGFR inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), due to high objective response rates with this regimen. For patients who decline or are ineligible for immunotherapy, a single-agent VEGFR inhibitor (eg, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>) is a reasonable alternative. (See <a class="local">'Translocation renal cell carcinoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unclassified renal cell carcinoma </strong>– For patients with advanced or metastatic unclassified RCC, we suggest initial therapy with immunotherapy-based regimens rather than VEGFR inhibitors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), due to high objective response rates with this approach. Options include combination therapy (<a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>; <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>) or single-agent immunotherapy (pembrolizumab  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 2</a>) or nivolumab  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 5</a>)). Recognizing that there are limited data directly comparing these regimens, we feel any of these options are appropriate. (See <a class="local">'Unclassified renal cell carcinoma'</a> above.)</p><p></p><p class="bulletIndent1">For patients who decline or are ineligible for immunotherapy, VEGFR inhibitors are a reasonable alternative, either as single agents (eg, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>), or as combination therapy (eg, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-clear cell</strong> <strong>renal carcinoma with sarcomatoid features </strong>– For patients with treatment-naïve advanced or metastatic non-clear cell RCC with sarcomatoid features, we prefer immunotherapy-based regimens. (See  <a class="medical medical_review" href="/d/html/128561.html" rel="external">"Renal cell carcinoma with sarcomatoid features", section on 'Initial therapy (non-clear cell RCC with sarcomatoid features)'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">WHO classification of tumours of the urinary system and male genital organs, Moch H, Humphrey PA, Ulbright TM, Reuter VE (Eds), World Health Organization, Lyon 2016.</li><li><a class="nounderline abstract_t">Vera-Badillo FE, Templeton AJ, Duran I, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol 2015; 67:740.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376.</a></li><li><a class="nounderline abstract_t">Ronnen EA, Kondagunta GV, Ishill N, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006; 107:2617.</a></li><li><a class="nounderline abstract_t">Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005; 28:488.</a></li><li class="breakAll">Pal SK, Choueiri TK. Systemic Therapies for Metastatic Renal Cell Carcinoma of Variant Histology. In: Renal Cell Carcinoma, Tannir NM (Ed), Oxford American Oncology Library, New York 2014.</li><li><a class="nounderline abstract_t">Klatte T, Pantuck AJ, Said JW, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 2009; 15:1162.</a></li><li><a class="nounderline abstract_t">Stamatakis L, Singer EA, Siddiqui MM, et al. Phase II trial of bevacizumab and erlotinib in patients with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell carcinoma. Eur J Cancer 2011; abstract 2753.</a></li><li class="breakAll">Srinivasan R, et al. Mechanism based targeted therapy for hereditary leimyomatosis and renal cell cancer and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib (abstract 5). EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (2014).</li><li><a class="nounderline abstract_t">Srinivasan R, Gurram S, al Harthy M, et al. Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. J Clin Oncol 2020; 38:5004.</a></li><li><a class="nounderline abstract_t">Gleeson JP, Nikolovski I, Dinatale R, et al. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clin Cancer Res 2021; 27:2910.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Heng DYC, Lee JL, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol 2020; 6:1247.</a></li><li class="breakAll">Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT05043090 (Accessed on March 06, 2022).</li><li><a class="nounderline abstract_t">Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018; 378:1277.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20:1370.</a></li><li><a class="nounderline abstract_t">McKay RR, Bossé D, Xie W, et al. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer Immunol Res 2018; 6:758.</a></li><li><a class="nounderline abstract_t">Chahoud J, Msaouel P, Campbell MT, et al. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist 2019.</a></li><li><a class="nounderline abstract_t">Gupta R, Ornstein MC, Li H, et al. Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma. Clin Genitourin Cancer 2020; 18:429.</a></li><li><a class="nounderline abstract_t">Tykodi SS, Gordan LN, Alter RS, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer 2022; 10.</a></li><li><a class="nounderline abstract_t">Albiges L, Gurney H, Atduev V, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2023; 24:881.</a></li><li><a class="nounderline abstract_t">Lee CH, Voss MH, Carlo MI, et al. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. J Clin Oncol 2022; 40:2333.</a></li><li><a class="nounderline abstract_t">Koshkin VS, Barata PC, Zhang T, et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer 2018; 6:9.</a></li><li><a class="nounderline abstract_t">Geynisman DM. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015; 68:912.</a></li><li><a class="nounderline abstract_t">McDermott DF, Lee JL, Ziobro M, et al. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. J Clin Oncol 2021; 39:1029.</a></li><li><a class="nounderline abstract_t">Vogelzang NJ, Olsen MR, McFarlane JJ, et al. Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clin Genitourin Cancer 2020; 18:461.</a></li><li><a class="nounderline abstract_t">Atkins MB, Jegede OA, Haas NB, et al. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). J Immunother Cancer 2023; 11.</a></li><li><a class="nounderline abstract_t">Ciccarese C, Iacovelli R, Brunelli M, et al. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. Eur J Cancer 2017; 83:237.</a></li><li><a class="nounderline abstract_t">Campbell MT, Bilen MA, Shah AY, et al. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer 2018; 104:188.</a></li><li><a class="nounderline abstract_t">Martínez Chanzá N, Xie W, Asim Bilen M, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol 2019; 20:581.</a></li><li><a class="nounderline abstract_t">Pal SK, Tangen C, Thompson IM Jr, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet 2021; 397:695.</a></li><li><a class="nounderline abstract_t">Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. Ann Oncol 2015; 26:1123.</a></li><li><a class="nounderline abstract_t">Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol 2016; 17:378.</a></li><li><a class="nounderline abstract_t">Tannir NM, Jonasch E, Albiges L, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol 2016; 69:866.</a></li><li><a class="nounderline abstract_t">Knox JJ, Barrios CH, Kim TM, et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol 2017; 28:1339.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32:2765.</a></li><li><a class="nounderline abstract_t">Irshad T, Olencki T, Zynger L, et al. Bevacizumab in metastatic papillary renal cell carcinoma (PRCC). J Clin Oncol 2011; 29 (suppl):abstract e15158.</a></li><li><a class="nounderline abstract_t">Jung KS, Lee SJ, Park SH, et al. Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. Cancer Res Treat 2018; 50:488.</a></li><li><a class="nounderline abstract_t">Park I, Lee SH, Lee JL. A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus. Clin Genitourin Cancer 2018; 16:e997.</a></li><li><a class="nounderline abstract_t">Buti S, Bersanelli M, Maines F, et al. First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. Clin Genitourin Cancer 2017; 15:e609.</a></li><li><a class="nounderline abstract_t">Negrier S, Rioux-Leclercq N, Ferlay C, et al. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. Eur J Cancer 2020; 129:107.</a></li><li><a class="nounderline abstract_t">Escudier B, Molinie V, Bracarda S, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer 2016; 69:226.</a></li><li><a class="nounderline abstract_t">Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271.</a></li><li><a class="nounderline abstract_t">Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26:202.</a></li><li><a class="nounderline abstract_t">Schöffski P, Wozniak A, Escudier B, et al. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur J Cancer 2017; 87:147.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31:181.</a></li><li><a class="nounderline abstract_t">Suárez C, Larkin JMG, Patel P, et al. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). J Clin Oncol 2023; 41:2493.</a></li><li><a class="nounderline abstract_t">Voss MH, Molina AM, Chen YB, et al. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. J Clin Oncol 2016; 34:3846.</a></li><li><a class="nounderline abstract_t">Davis CF, Ricketts CJ, Wang M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014; 26:319.</a></li><li><a class="nounderline abstract_t">Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012; 62:1013.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127.</a></li><li><a class="nounderline abstract_t">Schwartz C, Pfanzelter N, Kuzel TM. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review. Clin Genitourin Cancer 2017; 15:e903.</a></li><li><a class="nounderline abstract_t">Hutson TE, Michaelson MD, Kuzel TM, et al. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. Eur Urol 2021; 80:162.</a></li><li><a class="nounderline abstract_t">McGregor BA, McKay RR, Braun DA, et al. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol 2020; 38:63.</a></li><li><a class="nounderline abstract_t">Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J Urol 2007; 177:1698.</a></li><li><a class="nounderline abstract_t">Pécuchet N, Bigot F, Gachet J, et al. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. Ann Oncol 2013; 24:2963.</a></li><li><a class="nounderline abstract_t">Gollob JA, Upton MP, DeWolf WC, Atkins MB. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 2001; 58:1058.</a></li><li><a class="nounderline abstract_t">Milowsky MI, Rosmarin A, Tickoo SK, et al. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 2002; 94:111.</a></li><li><a class="nounderline abstract_t">Peyromaure M, Thiounn N, Scotté F, et al. Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 2003; 170:1138.</a></li><li><a class="nounderline abstract_t">Panunzio A, Sorce G, Tappero S, et al. Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma. Clin Genitourin Cancer 2023; 21:295.</a></li><li><a class="nounderline abstract_t">Strouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 2005; 44:407.</a></li><li><a class="nounderline abstract_t">Walsh A, Kelly DR, Vaid YN, et al. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer 2010; 55:1217.</a></li><li><a class="nounderline abstract_t">Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: the Bronx experience. Urology 2007; 70:878.</a></li><li><a class="nounderline abstract_t">Maroja Silvino MC, Venchiarutti Moniz CM, Munhoz Piotto GH, et al. Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil. Rare Tumors 2013; 5:e44.</a></li><li><a class="nounderline abstract_t">Shah AY, Karam JA, Malouf GG, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int 2017; 120:782.</a></li><li><a class="nounderline abstract_t">Schaeffer EM, Guzzo TJ, Furge KA, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int 2010; 106:62.</a></li><li><a class="nounderline abstract_t">Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22:3720.</a></li><li><a class="nounderline abstract_t">Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol 2006; 24:e14.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010; 116:5219.</a></li><li><a class="nounderline abstract_t">Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 2010; 21:1834.</a></li><li><a class="nounderline abstract_t">Feldman DR, Ged Y, Lee CH, et al. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer 2020; 126:5247.</a></li></ol></div><div id="topicVersionRevision">Topic 96030 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : WHO classification of tumours of the urinary system and male genital organs, Moch H, Humphrey PA, Ulbright TM, Reuter VE (Eds), World Health Organization, Lyon 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24882670" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981011" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17083126" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment outcome for metastatic papillary renal cell carcinoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16113605" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16113605" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19228721" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Phase II trial of bevacizumab and erlotinib in patients with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell carcinoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Phase II trial of bevacizumab and erlotinib in patients with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell carcinoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33658299" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469384" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469384" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562145" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31427204" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29748390" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31501271" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32800717" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35210307" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37451291" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35298296" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29378660" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26194044" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33529058" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32718906" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36948504" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28756136" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30380460" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30827746" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33592176" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25802238" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26794930" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26626617" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28327953" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25049330" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bevacizumab in metastatic papillary renal cell carcinoma (PRCC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28546525" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29903415" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28108284" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32146304" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27680407" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538086" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19229667" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29149761" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23213094" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36809050" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27601542" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25155756" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The somatic genomic landscape of chromophobe renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22771265" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18165647" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28624319" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33867192" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31721643" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437788" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24190963" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11744492" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11815966" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14501710" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36117092" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15602719" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Significant responses to platinum-based chemotherapy in renal medullary carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20979179" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068443" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Renal medullary carcinoma: the Bronx experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24179656" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27860149" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20002663" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365068" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Phase II trial of bortezomib for patients with advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549825" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Medullary renal cell carcinoma and response to therapy with bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20665500" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20154303" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32975815" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
